Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tl-3-093
- Development stage
- Unknown
- Modality
- Small Molecules, Peptides
01
Overview
Tl‑3‑093 is an experimental small molecule dipeptide derivative with the chemical formula C25H33N3O5 and a molecular weight of approximately 455.5 g/mol. It is classified as a dipeptide, specifically N-benzoxycarbonyl-L-alanyl-L-valyl-L‑phenylalaninol (Cbz-Ala-Val-Pheol). The compound has been studied in medicinal chemistry and drug discovery, but there are no approved indications or advanced clinical trials reported for this agent. Its precise mechanism of action and therapeutic target have not been publicly disclosed[1][3][2].
- Other names
- benzyl N-[(1S)-1-{[(1S)-1-{[(2S)-1-hydroxy-3-phenylpropan-2-yl]carbamoyl}-2-methylpropyl]carbamoyl}ethyl]carbamatebenzyl N-((1S)-1-(((1S)-1-(((2S)-1-hydroxy-3-phenylpropan-2 yl)carbamoyl)-2-methylpropyl)carbamoyl)ethyl)carbamateCbz-Ala-Val-Phe-alcohol (Cbz-Ala-Val-Pheol)
Beyond the preview
Go deeper on Tl-3-093.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tl-3-093.